Vaccines, Blood & Biologics

October 3, 2013 Approval Letter - Menomune - A/C/Y/W - 135

Our STN:BLS 103926/5178

Sanofi Pasteur Inc.
Attention:Joseph H. Quinn
1 Discovery Drive
Swiftwater, PA18370

Dear Mr. Quinn:

We have approved your request to supplement to your biologics license application for

Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W-135 Combined, Menomune®-A/C/Y/W-135, to include revisions to the NDC and the Package Insert, 2D Barcode additions and modification of the single dose detachable label.

Please provide your final content of labeling in Structured Product Labeling (SPL) format and include the carton and container labels.In addition, please submit three original paper copies for carton and container final printed labeling. All final labelingshould be submitted as Product Correspondence to this BLAat the time of use (prior to marketing) and include implementation information on FDA Form 356h.

In addition, please submit the final content of labeling (21 CFR 601.14) in SPL format via the FDA automated drug registration and listing system, (eLIST), as described at on submitting SPL files using eLIST may be found in the guidance for industry titled, “SPL Standard for Content of Labeling Technical Qs and As” at

You may submit two draft copies of the proposed introductory advertising and promotional labeling with an FDA Form 2253 to the Center for Biologics Evaluation and Research, Advertising and Promotional Labeling Branch, HFM-602, 1401 Rockville Pike, Rockville, MD 20852-1448. You must submit copies of your final advertisement and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f) (4)).

All promotional claims must be consistent with and not contrary to approved labeling.You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims

(21 CFR 202.1(e) (6)).

We will include information contained in the above-referenced supplement in your biologics license application file.

Sincerely yours,

Wellington Sun, M.D.
Division of Vaccines and
Related Products Applications
Office of Vaccines
Research and Review
Center for Biologics
Evaluation and Research

Attachment: Approved Final Draft Labeling

Resources for You

Page Last Updated: 05/05/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.